| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, …
Over the last 12 months, insiders at Indaptus Therapeutics, Inc. have bought $0 and sold $0 worth of Indaptus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Indaptus Therapeutics, Inc. have bought $203,142 and sold $100,043 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,934 shares for transaction amount of $56,006 was made by Anderson Glen R. (10 percent owner) on 2023‑08‑14.
| 2023-08-14 | Anderson Glen R. | 10 percent owner | 23,934 0.2688% | $2.34 | $56,006 | -11.29% | ||
| 2023-08-11 | Anderson Glen R. | 10 percent owner | 35,064 0.3798% | $2.12 | $74,336 | -4.35% | ||
| 2023-08-10 | Anderson Glen R. | 10 percent owner | 44,354 0.482% | $1.94 | $86,047 | -0.45% | ||
| 2022-12-01 | Litchev Boyan Vesselinov | Chief Medical Officer | 500 0.0063% | $1.87 | $935 | +8.94% | ||
| 2022-11-22 | Litchev Boyan Vesselinov | Chief Medical Officer | 500 0.0061% | $1.83 | $915 | +4.95% | ||
| 2022-11-21 | Meckler Jeffrey A | CEO and Director | 9,600 0.122% | $1.90 | $18,240 | +4.97% | ||
| 2022-11-18 | Meckler Jeffrey A | CEO and Director | 400 0.0047% | $1.76 | $705 | +4.97% | ||
| 2022-09-08 | Meckler Jeffrey A | CEO and Director | 10,308 0.1329% | $2.80 | $28,862 | -29.66% | ||
| 2022-09-07 | Linscott Walt Addison | Chief Business Officer | 150 0.0018% | $2.62 | $393 | -29.39% | ||
| 2022-09-06 | Meckler Jeffrey A | CEO and Director | 8,632 0.1092% | $2.57 | $22,184 | -24.80% | ||
| 2022-06-06 | Meckler Jeffrey A | CEO and Director | 19,727 0.2371% | $2.63 | $51,882 | -28.68% | ||
| 2022-03-02 | Litchev Boyan Vesselinov | Chief Medical Officer | 50 0.0006% | $4.09 | $205 | -42.65% | ||
| 2022-02-01 | Sale | Newman Michael James | CSO and Director | 14,130 0.1722% | $5.00 | $70,692 | -49.70% | |
| 2022-01-31 | Sale | Newman Michael James | CSO and Director | 5,870 0.0712% | $5.00 | $29,351 | -49.90% | |
| 2022-01-31 | Litchev Boyan Vesselinov | Chief Medical Officer | 100 0.0011% | $4.65 | $465 | -49.90% | ||
| 2021-11-18 | Meckler Jeffrey A | CEO and Director | 11,187 0.2847% | $5.82 | $65,108 | -44.81% | ||
| 2021-09-14 | Meckler Jeffrey A | CEO and Director | 12,000 0.2842% | $7.00 | $84,000 | -43.28% |
| Anderson Glen R. | 10 percent owner | 1190400 1.0512% | $3.86M | 3 | 0 | |
| Meckler Jeffrey A | CEO and Director | 75374 0.0666% | $244,211.76 | 7 | 0 | <0.0001% |
| Litchev Boyan Vesselinov | Chief Medical Officer | 1150 0.001% | $3,726.00 | 4 | 0 | <0.0001% |
| Linscott Walt Addison | Chief Business Officer | 150 0.0001% | $486.00 | 1 | 0 |
$31,123,523 | 108 | 6.46% | $387.86M | |
$24,384,691 | 42 | -30.27% | $396.82M | |
$2,471,510 | 19 | 17.33% | $334.18M | |
$10,399,379 | 13 | 13.60% | $302.03M | |
$57,263,116 | 11 | -8.37% | $386.95M |
| Increased Positions | 2 | +40% | 31,178 | +155.72% |
| Decreased Positions | 2 | -40% | 19,005 | -94.92% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | <1 | Sold Out | 18,997 | Sold Out |
| Total Postitions | 5 | 0% | 32,195 | +60.8% |
| Virtu Financial Llc | $52.00 | 0.95% | 18,997 | +18,997 | New | 2025-09-30 |
| Ubs Group Ag | $1.00 | 0.03% | 502 | +502 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.02% | 473 | +365 | +337.96% | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | <0.01% | 33 | +2 | +6.45% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 17 | -139 | -89.1% | 2025-09-30 |
| Fmr Llc | $0 | 0% | 0 | -10 | Sold Out | 2025-09-30 |
| Wells Fargo & Company/Mn | $0 | 0% | 0 | -2 | Sold Out | 2025-09-30 |